Weight Loss News and Research

Latest Weight Loss News and Research

Community-based wellness program helps reduce obesity, chronic inflammatory diseases: Study

Tackling weight loss, risk of chronic disease and overall well-being as part of a like-minded social community can dramatically influence an individual's success rate, according to a new study published in the July 2010 issue of the Center for Disease Control's Preventing Chronic Disease journal.

9 Jul 2010

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

The U.S. Food and Drug Administration today warned that Que She, marketed as an herbal weight loss supplement, contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions.

9 Jul 2010

Smart for Life Cookie Diet selected to receive 2010-2011 Shining Star Award

The trailblazing company whose Smart for Life weight management products featuring the Smart for Life Cookie Diet component was recently selected to receive the Unicorn Children's Foundation 2010-2011 Shining Star Award. This award recognizes an individual or organization that has brought significant awareness to the issues associated with developmental, communication, and learning disorders.

8 Jul 2010

Dietary protein intake may reduce bone density in overweight, postmenopausal women: Research

Overweight and moderately obese postmenopausal women using diets based on higher protein intake also need to be aware of potential bone loss, according to new research from Purdue University.

8 Jul 2010

Physical activity has little role to play in obesity epidemic among children: EarlyBird Diabetes Study

A new report from the EarlyBird Diabetes Study suggests that physical activity has little if any role to play in the obesity epidemic among children. Obesity is the key factor behind diabetes, heart disease and some cancers.

8 Jul 2010

Researchers show unexpected, physiological effects of water

Name a drink that can make you more alert for late-night studying, prevent you from fainting after giving blood, and even promote a teensy bit of weight loss. Chances are you didn't say water. But that's the right answer.

7 Jul 2010

Medifast announces grand opening of Texas Distribution Center in Coppell

Medifast, Inc. today announced the grand opening of a 50,000 square foot Texas Distribution Center located in Coppell, Tx., just outside of Dallas. The facility will support West Coast shipping for Medifast Direct; Take Shape For Life, Medifast's personal coaching division; and Medifast Weight Control Centers.

7 Jul 2010

POMC neurons suppress appetite, induce weight loss: Research

A protein found in cells throughout the body must be present in a specific set of neurons in the brain to prevent weight gain after chronic feeding on high-calorie meals, new findings from UT Southwestern Medical Center researchers suggest.

7 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Independence Blue Cross announces five new Personal Choice PPO plans

Beginning July 1, 2010, Independence Blue Cross (IBC) will offer five new Personal Choice® PPO plan options for individuals – expanding the range of individual plan choices for health care consumers in the region. These medically underwritten plans are available in three popular formats: copay, deductible and health savings account (HSA) plan designs that enable consumers to choose the type of plan and pricing that fits their specific needs.

30 Jun 2010

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.

30 Jun 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Weight Loss News and Research

Latest Weight Loss News and Research

Community-based wellness program helps reduce obesity, chronic inflammatory diseases: Study

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

Smart for Life Cookie Diet selected to receive 2010-2011 Shining Star Award

Dietary protein intake may reduce bone density in overweight, postmenopausal women: Research

Physical activity has little role to play in obesity epidemic among children: EarlyBird Diabetes Study

Researchers show unexpected, physiological effects of water

Medifast announces grand opening of Texas Distribution Center in Coppell

POMC neurons suppress appetite, induce weight loss: Research

Plant extract effective against ulcerative colitis in mice

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Independence Blue Cross announces five new Personal Choice PPO plans

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

BBD reports analyze effectiveness and safety of statin use

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Weight Loss News and Research

Latest Weight Loss News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in